Related Experiment Videos
The managed care pharmacy perspective.
The American Journal of Managed Care
|December 1, 2001
Summary
Hormonal therapies like oral contraceptives and hormone replacement therapy offer significant health benefits but are underused. Despite initial pharmacy costs, they reduce overall healthcare expenses by preventing unintended pregnancies and improving women's health.
Area of Science:
- Reproductive Endocrinology
- Pharmacoeconomics
- Women's Health
Background:
- Oral contraceptives (OCs) and hormone replacement therapy (HRT) provide crucial reproductive and noncontraceptive health benefits.
- Despite these advantages, utilization rates for OCs and HRT remain low among eligible women.
- Managed care organizations exhibit significant variation in hormonal therapy coverage, reflecting cost containment concerns.
Purpose of the Study:
- To evaluate the pharmacoeconomic impact of hormonal therapy utilization.
- To analyze the relationship between pharmacy costs and overall healthcare expenditures for OCs and HRT.
- To highlight the cost-effectiveness of hormonal therapies in women's healthcare.
Main Methods:
- Review of existing pharmacoeconomic research on hormonal therapy.
- Analysis of healthcare cost data associated with hormonal therapy use.
- Examination of cost-benefit analyses for OCs and HRT.
Main Results:
- Increased use of hormonal therapy leads to higher pharmacy costs.
- However, these therapies significantly reduce overall patient healthcare costs.
- Prevention of unintended pregnancies by OCs and noncontraceptive benefits of OCs/HRT contribute to cost savings.
Conclusions:
- Pharmacoeconomic research indicates that hormonal therapies are cost-effective interventions.
- Despite pharmacy cost concerns, the health benefits and cost savings associated with OCs and HRT justify their use.
- Optimizing access to and utilization of hormonal therapy can lead to improved women's health outcomes and reduced societal healthcare burden.